Evidence map›Paper›PMID 37082748›Full record

ArticleACS pharmacology & translational science2023

New Xanthone Derivatives as Potent G-Quadruplex Binders for Developing Anti-Cancer Therapeutics.

Soma Roy, Bappa Maiti, Nilanjan Banerjee, Mangesh H Kaulage, Kalappa Muniyappa, Subhrangsu Chatterjee, Santanu Bhattacharya

Abstract read
In one paragraph

Article in ACS pharmacology & translational science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Soma RoyDepartment of Organic Chemistry, Indian Institute of Science, Bangalore 560012, India.
Bappa MaitiSchool of Applied & Interdisciplinary Sciences, Indian Association for the Cultivation of Science, Kolkata 700032, India.
Nilanjan BanerjeeDepartment of Biophysics, Bose Institute, P-1/12 CIT Scheme VII (M), Kolkata 700054, India.
Mangesh H KaulageDepartment of Biochemistry, Indian Institute of Science, Bangalore 560012, India.
Kalappa MuniyappaDepartment of Biochemistry, Indian Institute of Science, Bangalore 560012, India.ORCID https://orcid.org/0000-0002-9192-9194
Subhrangsu ChatterjeeDepartment of Biophysics, Bose Institute, P-1/12 CIT Scheme VII (M), Kolkata 700054, India.ORCID https://orcid.org/0000-0002-3250-7311
Santanu BhattacharyaDepartment of Organic Chemistry, Indian Institute of Science, Bangalore 560012, India.ORCID https://orcid.org/0000-0001-9040-8971

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Xanthone is an important scaffold for various medicinally relevant compounds. However, it has received scant attention in the design of agents that are cytotoxic to cancer cells via targeting the stabilization of G-quadruplex (G4) nucleic acids. Specific G4 DNA recognition against double-stranded (ds) DNA is receiving epoch-making interest for the development of G4-mediated anticancer agents. Toward this goal, we have synthesized xanthone-based derivatives with various functionalized side-arm substituents that exhibited significant selectivity for G4 DNA as compared to dsDNA. The specific interaction has been demonstrated by performing various biophysical experiments. Based on the computational study as well as the competitive ligand binding assay, it is inferred that the potent compounds exhibit an end-stacking mode of binding with G4 DNA. Additionally, compound-induced conformational changes in the flanking nucleotides form the binding pocket for effective interaction. Selective action of the compounds on cancer cells suggests their effectiveness as potent anti-cancer agents. This study promotes the importance of structure-based screening approaches to get molecular insights for new scaffolds toward desired specific recognition of non-canonical G4 DNA structures.

Identifiers

PMID37082748
PMCPMC10111628

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.